Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of May 2023. The report, dated May 23, 2023, serves as a vehicle to disseminate a press release (Exhibit 99.1) to U.S. investors. The company is headquartered in Marseille, France.
Key Financial Metrics
The filing text provided does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document. The filing acts solely as a reference to an external press release.
Material Changes
The filing does not detail material changes versus prior periods. It references a press release dated May 23, 2023, but the content of that release is not included in the provided text.
Guidance, Outlook, and Risks
There is no management commentary, guidance, outlook, or discussion of risks and contingencies within the body of this Form 6-K. The document is a procedural filing to attach a press release.
Investor Verification Checklist
- Verify the content of the referenced Press Release dated May 23, 2023 (Exhibit 99.1), as the specific news or data is not in this text.
- Confirm the company's status as a registrant filing under Form 20-F.
- Review the signature of Mondher Mahjoubi, Chairman of the Executive Board and CEO, authorizing the report.